News

Bringing Innovation in Single Particle Automated Raman Trapping Analysis to the Japanese Market

London – Tokyo, 10th of July 2025

Meiwafosis CO., LTD. has signed an official distributorship agreement with SPARTA Biodiscovery to distribute their advanced single particle analysis platform, the SPARTA Platform.

SPARTA Biodiscovery’s unique technology enables non-destructive and label-free analysis of nanoparticle structure, composition and functionalisation at the single particle level. The company’s proprietary technology brings innovation to research areas such as nanomedicines, extracellular vesicles (EVs), mRNA therapeutics, viral vectors, and polymer carriers.

The SPARTA AGIS I (Single Particle Automated Raman Trapping Analysis) is the world’s first automated platform that combines optical trapping and Raman spectroscopy, enabling analysis of heterogeneity between particles, degree of functionalization, and real-time reaction tracking, which are often overlooked by conventional bulk analysis. This allows researchers to more precisely and quickly optimize particle design and manufacturing processes.

Meiwafosis will provide comprehensive support for the introduction of SPARTA Biodiscovery products in Japan, including technical training, training at the time of installation, demonstration measurements, conference exhibitions, and after-sales support, and will provide both technical and operational backup so that researchers in Japan can make the most of cutting-edge particle analysis.